Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
22 Feb 24
8-K
Kymera Therapeutics Announces Proposed Public Offering
5 Jan 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
4 Jan 24
8-K
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
2 Nov 23
8-K
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
2 Nov 23
8-K
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
22 May 23
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
424B5
Prospectus supplement for primary offering
5 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
S-8
Registration of securities for employees
23 Feb 23
424B3
Prospectus supplement
6 Sep 22
S-8
Registration of securities for employees
24 Feb 22
S-3ASR
Automatic shelf registration
1 Oct 21
424B4
Prospectus supplement with pricing info
2 Jul 21
S-1MEF
Registration of additional securities for an S-1
30 Jun 21
S-1
IPO registration
28 Jun 21
Other
EFFECT
Notice of effectiveness
1 Jul 21
CORRESP
Correspondence with SEC
28 Jun 21
CORRESP
Correspondence with SEC
28 Jun 21
UPLOAD
Letter from SEC
19 Mar 21
SEC STAFF
SEC staff action: Order
11 Mar 21
SEC STAFF
SEC staff action: Order
10 Feb 21
EFFECT
Notice of effectiveness
21 Aug 20
CERT
Certification of approval for exchange listing
20 Aug 20
CORRESP
Correspondence with SEC
18 Aug 20
CORRESP
Correspondence with SEC
18 Aug 20
Ownership
SC 13D
BAKER BROS. ADVISORS LP
1 Apr 24
4
JULIAN BAKER
1 Apr 24
3
Initial statement of insider ownership
1 Apr 24
4
Bruce Booth
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Change in insider ownership
13 Mar 24
4
Bruce Booth
13 Mar 24